C
OPD is a major health burden worldwide. It is the fourth-leading cause of mortality, accounting for Ͼ 3 million deaths annually; and by 2020, COPD will be the third-leading cause of death, trailing only ischemic heart disease and stroke. 1 Most COPDrelated deaths occur during periods of exacerbation. 2, 3 Previous studies 2 estimate that 50 to 70% of all COPD exacerbations are precipitated by an infectious process, while 10% are due to environmental pollution. Up to 30% of exacerbations are caused by an unknown etiology. 2 Exacerbations are charac-
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terized by increase in cough and dyspnea. A study 4 suggests that patients with COPD have approximately twice the risk of pulmonary embolism (PE) and other venous thromboembolic events (venous thromboembolism [VTE] ) than those without COPD. Since thromboembolic events can lead to cough and dyspnea (just like infectious events), PE may be another common cause of COPD exacerbations. 5 However, dissimilar to infectious etiologies, which are effectively treated by antimicrobials and systemic corticosteroids, thromboembolic diseases require anticoagulant therapy and significant delays in treatment are associated with poor outcomes. 6 Owing to multiple perfusion and ventilation abnormalities frequently observed in COPD lungs (even in the absence of VTE), noninvasive diagnosis of PE using imaging modalities was a significant challenge until quite recently. With the advent of contrastenhanced (multidetector) CT, it is now possible to reliably diagnose PE in COPD subjects with minimal discomfort or risk to the patients. The primary purpose of this review was to determine the reported prevalence of PE in patients with COPD who required hospitalization for their disease.
Materials and Methods

Data Searches and Study Selection
A comprehensive literature search for English and French articles was conducted using MEDLINE (1949 ( -April 2008 , CINAHL (1982 -April 2008 , and EMBASE (1980 -April 2008). Search terms for VTE, which included "pulmonary embolism," "PE," "thromboembolism," or "venous thromboembolism" were combined with those for COPD, which included "COPD," "COPD exacerbation," "emphysema," and "bronchitis." This process was complemented by hand searching of bibliographies of retrieved articles to find additional articles that may have been missed during the electronic search.
We limited our search to studies that met the following criteria: (1) estimated the prevalence of PE during exacerbations of COPD; (2) were either cross-sectional or prospective in design; (3) enrolled patients Ն 18 years old, who did not have another obvious cause for the respiratory deterioration such as sepsis/ bacteremia, malignancy, pneumothorax, or myocardial infarction; (4) enrolled patients with COPD diagnosed based on clinical symptoms and spirometry; and (5) employed either contrastenhanced CT angiography or pulmonary angiography within 48 h of presentation to a health-care service facility. We excluded studies for the following: (1) retrospective design; (2) PE diagnosis strictly based on ventilation/perfusion (V /Q ) scanning, autopsy, or occurrence of deep vein thrombosis (DVT); or (3) published only in abstract form.
Data Extraction
From the retrieved articles, data abstraction was performed, which included the following: study location; date, design, and setting (emergency department, inpatients, outpatients, or ICUs); number of centers involved; number of patients enrolled; mean age; sex; medical history (including malignancy, prior DVT or PE, thrombophilia, recent trauma, surgery, immobilization, paralysis, congestive heart failure, severity of COPD); medication use (especially birth control pills or hormone replacement therapy); pulmonary function test results; arterial blood gas levels; smoking history; use of domiciliary oxygen; family history of DVT or PE; clinical presentation on arrival to a health-care facility (including dyspnea, chest pain, hemoptysis, cough, syncope); physical examination (including heart rate, respiratory rate, temperature, BP, signs of right ventricular failure, edema of the lower limbs); chest radiographic findings; ECG findings; diagnostic tests for VTE (blood d-dimer levels, lower-leg ultrasound, V /Q scan, contrastenhanced CT, or pulmonary angiography), prevalence of DVT and PE; follow-up after discharge; and mortality.
Statistical Analysis
Where possible the prevalence estimates for PE and DVT (collectively referred to as VTE) were combined using the sample size of each retrieved study as weights. A priori, we hypothesized that the prevalence of PE and DVT would be higher among patients who were hospitalized than those who were investigated as outpatients or in the emergency departments. We thus classified the studies into two categories: (1) studies that investigated patients who required hospitalization; and (2) studies that investigated patients in the emergency department or as an outpatient. The quality of the included studies were assessed using the Strengthening the Reporting of Observational Studies in Epidemiology 7 guidelines; t tests (with two tails) were used to determine whether the (aggregated) prevalence estimates were Ͼ 0%. All analyses were conducted using statistical software (SAS version 9.1; SAS Institute; Cary, NC).
Results
Study Selection
A total of 2,407 articles were identified using the MEDLINE, CINAHL, and Embase search engines; 2,384 articles were excluded because they did not meet the inclusion criteria or were multiple articles from the same cohort. The remaining 23 articles were retrieved for detailed examination. Of these, 11 articles were excluded for the following reasons on further review: (1) they contained a significant selection bias for VTE; (2) they did not employ CT scanning or pulmonary angiography in their diagnostic workup for VTE; (3) they lacked objective diagnosis of COPD (using spirometry); or (4) they employed a retrospective study design. An additional six articles were excluded because they were not original articles, and one study was excluded because it did not contain any prevalence estimates of VTE. This left five articles for analysis. The selection process for this review is summarized in Figure 1 .
Characteristics of the Included Studies
The clinical and study characteristics of the selected articles are summarized in Tables 1, 2 . Of the five studies, 8 -12 four studies 8,10 -12 were published between 2000 and 2007, and one study 9 was published in 1992. The total number of patients assessed in these studies was 550, with a range of 31 to 197 subjects per study. Mean age of the patients ranged from 56 to 71 years, and the percentage of male subjects was from 43 to 84%. The studies were conducted in various European countries and the United States; two of the studies were conducted in France but at different institutions. The study by Rutschmann et al 11 was the only study that investigated the prevalence of PE in COPD patients presenting to the emergency department, while the remaining four studies evaluated patients who were hospitalized. The two studies 8,9 also included patients presenting in the outpatient department with an exacerbation of COPD.
Prevalence of VTE During COPD Exacerbations
The prevalence estimates for VTE for each of the study are summarized in Table 1 . Overall, the prevalence of PE in these studies was 19.9% (95% confidence interval [CI], 6.7 to 33.0%; p ϭ 0.014). In a sensitivity analysis, we excluded the largest of the study (ie, Tillie-Leblond et al 12 ) and found that the overall prevalence of PE was similar at 17.0% (p ϭ 0.072), although no longer significant owing to a smaller sample size. In the four studies that included hospitalized COPD patients, the prevalence was higher at 24.7% (95% CI, 17.9 to 31.4%; p ϭ 0.001). The one study 11 that included only patients in the emergency department had a lower prevalence of PE (3.3%) [Fig 2] . In the two studies that exclusively evaluated patients who were hospitalized for COPD exacerbation, 10,12 the prevalence of PE was 25.5% (95% CI, 8.1 to 43.0%; p ϭ 0.034).
In the two studies that included both inpatients and outpatients with a COPD exacerbation, the prevalence of PE was slightly lower at 23.6% (95% CI, Ϫ 39.7 to 86.9%; p ϭ 0.133). 8, 9 In general, the prevalence of DVTs was lower than that of PE. The overall prevalence estimate of DVT was 12.4% (95% CI, Ϫ 2.2 to 27.1%; p ϭ 0.074). The prevalence was higher in the group that evaluated hospitalized patients (prevalence estimate, 16.6%; 95% CI, 1.1 to 32.1%; p ϭ 0.044).
Prevalence of Risk Factors for VTE
The prevalence of risk factors for VTE in each of the studies is summarized in Table 2 . Three studies 9,10,12 reported VTE risk factors in patients with and without PE. Tillie-Leblond et al 12 found that COPD patients with PE were more likely to have a history of VTE (relative risk [RR], 2.43; 95% CI, 1.49 to 3.49) or malignancy (RR, 1.82; 95% CI, 1.3 to 2.92) compared to COPD patients without PE. Overall, the prevalence of VTE risk factors was lower among patients who presented to an emergency department than those who required hospitalization. The prevalence of previous VTE, surgery, and cancer was 3%, 2%, and 5%, respectively, in the study by Rutschmann et al. 11 In contrast, it was 14%, 13%, and 10%, respectively, in the study by Hartmann et al. 8 
Clinical Presentation of COPD Patients Who Did and Did Not Have PE
Three studies 9,11,12 compared symptoms on presentation in COPD patients with and without PE. Tille-Leblond et al 12 and Lesser et al 9 failed to find significant differences in the occurrence of dyspnea, chest pain, hemoptysis, cough, or palpitations between these two groups. However, Rutschmann et al 11 found that patients with PE were more likely to complain of chest pain, syncope, and less likely to report cough or purulent sputum. In that study, 11 approximately 28% of the patients presented with chest pain (42% in those with PE and 19% in those without PE [p ϭ 0.008]). The chest pain was described as pleuritic (in 50% of the cases), oppressive (in 6% of the cases), reproduced by palpation (in 2% of the cases), and nonpleuritic (in 7% of the cases). The presence of cough was less frequent when PE was suspected (75% vs 93%, p ϭ 0.009). Syncope was the presenting complaint in 6% of patients with PE, but none presented with syncope if they did not have PE (p ϭ 0.051). In general, there were no significant differences in the physical examination findings between patients who did and did not have PE. Similarly, chest radiographic and ECG findings were similar between the two groups. The findings on arterial blood gas levels were discordant. Tillie-Leblond et al 12 noted a decrease in Paco 2 of at least 5 mm Hg from baseline in patients with PE (RR, 2.10; 95% CI, 1.23 to 3.58). However, this was not shown in other studies. 9, 10 Similarly, severity of hypoxemia was shown to be a risk factor for PE in two studies 10, 11 but not in another study. 12 
Other Considerations
There were some important differences in other characteristics between the studies. For instance, in the study by Tillie-Leblond et al, 12 the rate of malignancy was 29%, while it was 5% in the study by Rutschmann et al, 11 10% in the study by Hartmann et al, 8 10% in the study by Mispelaere et al, 10 and 13% in the study by Lesser et al. 9 There were also differences in the way PE was investigated between the studies. The case definition of PE in one study was a positive result on a contrast-enhanced CT angiogram or a positive finding on a lower-leg ultrasound. 12 In this study, the diagnosis of a PE was made in six patients who had a positive lower-limb ultrasound results but negative contrast-enhanced CT chest results. When these six patients are excluded, the rate of PE in this study decreased from 25 to 22%. Rutschmann et al 11 and Mispelaere et al, 10 however, excluded patients with a negative d-dimer test result, which may have led to an underdiagnosis of PE. Finally, the severity of the underlying COPD differed across the studies.
Discussion
The most important finding of our study was the relatively high prevalence of PE among patients who required hospitalization for acute exacerbations of COPD. Overall, one of four COPD patients who were hospitalized and investigated for VTE had objective evidence for PE requiring anticoagulant therapy. While striking, these data should be interpreted cautiously owing to the heterogeneity in the design, the setting, and enrollment criteria among the included studies.
Because symptoms of PE may be nonspecific, clinical prediction rules are used to reduce the need for imaging. Of the studies that were assessed, only one study 12 applied a validated clinical prediction rule (ie, a Geneva score 13 ) to determine the pretest probability of PE. It found that even patients in the low-risk category (a Geneva score Յ 4) had a substantive prevalence of PE (approximately 9%), although the prevalence was lower compared to those in the intermediate-risk category (a score of 5 to 8; 38% prevalence) or high-risk category (a score Ն 9; 46% prevalence). These data suggest that the Geneva risk scores may not be optimal in risk stratifying COPD patients for PE. Alternative instruments include the Wells criteria, 14 and the decision rule developed by Miniati et al, 15 although none of these have been well validated in COPD patients during exacerbations. Despite these shortcomings, the judicious use of these validated instruments in the context of a careful clinical and laboratory assessment may be helpful in avoiding unnecessary imaging studies.
Interestingly, we found that the prevalence of DVT was lower than that of PE in the same population. Although imaging techniques such as spiral CT scans are sensitive in detecting a filling defect in pulmonary arteries, a clear separation between in situ thrombosis and embolism (from peripheral veins) is not always possible. In one study 16 of 27 consecutive patients with stable COPD (mean FEV 1 , 52% of predicted) who did not have any history of VTE, transesophageal echocardiography revealed a lesion in central pulmonary arteries consistent with a thromboembolic event in 48% of these patients. Seventy-five percent of these lesions were flat or rounded and totally adherent to the right pulmonary artery, suggesting in situ thrombosis (rather than an embolic phenomenon). These findings in conjunction with data from the present study, which indicates a higher rate of PE than that of DVT raise the possibility that some of the PE cases may represent in situ thrombosis. This hypothesis will need to be validated in a prospective study.
There are several salient caveats to our findings. Firstly, all of the studies included in this analysis had relatively small sample sizes, making the prevalence estimates unstable. However, in studies that included hospitalized patients, the lower limit of the 95% CI was 18%, which suggests that even using a conservative approach, PE is likely to be common in acute exacerbations. Notably, there was one study 11 that evaluated patients in the emergency department and found a PE prevalence of 3.3%. Since patients requiring hospitalization are generally sicker, frailer, and have more comorbidities than those who do not, these findings suggest that other risk factors such as prolonged immobilization, cardiovascular disease, and cancer play important roles in the risk of PE during acute exacerbations. 17 Secondly, there are major clinical factors that modulate the risk for VTE, Figure 2 . The prevalence of PE across different sites. The filled circles represent the mean, and the line bars represent SE; p value for overall ϭ 0.014; p value for emergency department (ER) is not calculable because there was only one study; p value for studies that evaluated inpatients and outpatients ϭ 0.133; p value for studies that evaluated only hospitalized patients ϭ 0.034. and these factors could not be adequately evaluated in our study. For instance, one study 10 excluded subjects with low d-dimer levels, while another study 12 had an extraordinary high rate of malignancy in the population. Not surprisingly, the highest occurrence of VTE was observed in these two studies. It should also be noted that blood d-dimer levels have a high negative but a low positive predictive value for PE in COPD exacerbations because a multitude of different inflammatory and infectious etiologies can cause blood d-dimers to rise. 18 Notwithstanding these limitations, our findings may have some management implications for patients with COPD who require hospitalization. The standard in-hospital management of COPD exacerbations consists of bronchodilators, systemic corticosteroids, antimicrobials, and occasionally noninvasive mechanical ventilation. 19 While subcutaneous heparin may be administered in "prophylactic" doses, therapeutic doses are not routinely provided unless VTE is diagnosed. PEs are associated with high morbidity and mortality with a 3-month mortality rate of 15 to 18% even with adequate anticoagulant therapy. 20 In COPD patients, the risk of mortality nearly doubles. 20 Any delays in the diagnosis of PE or initiation of treatment significantly amplifies the risk of mortality. 6 In view of the high prevalence of VTE in COPD patients who require hospitalization and the mortality risk associated with undiagnosed VTE, PE should be carefully considered especially in those who have an intermediateto-high pretest probability of PE based on clinical assessment.
Our study findings also highlight the urgent need for a large-scale, multicenter study to evaluate the prevalence of VTE in COPD patients who do and do not require hospitalization. While systematic reviews and metaanalyses are useful tools to synthesize the existing body of evidence, they cannot substitute findings from well-conducted, large (multicenter) clinical studies. 21 Given the therapeutic and prognostic importance of a prompt diagnosis of PE during exacerbations, there is a pressing need to determine the prevalence as well as the clinical manifestations of PE-related exacerbations in patients with COPD. In the meantime, our study findings suggest that one in four patients with an acute exacerbation of COPD may have PE. Thus, clinicians should consider PE in the diagnostic workup of COPD exacerbations, especially in patients where the underlying etiology is not apparent and in whom there is a history of malignancy or other additional risk factors that may increase the clinical likelihood of PE.
